Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2007 1
2010 2
2011 3
2012 2
2021 2
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S, Alimonti A, Bifari F, Pani L, Folli F, Guidetti C, Furlan A, Sgrignani J, Locatelli P, Cavalli A, O'Gorman C, Traversa S, Inturrisi CE, Pappagallo M, Manfredi PL. Fava M, et al. Among authors: bettini e. Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1463-1476. doi: 10.1007/s00406-023-01571-4. Epub 2023 Mar 8. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 36890259 Free PMC article. Review.
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, Alimonti A, Bettini E, Mangano RM, Wessel T, de Somer M, Caron J, Vitolo OV, DiGuglielmo GR, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Folli F, Traversa S, Inturrisi CE, Manfredi PL. Fava M, et al. Among authors: bettini e. Am J Psychiatry. 2022 Feb;179(2):122-131. doi: 10.1176/appi.ajp.2021.21020197. Epub 2021 Dec 22. Am J Psychiatry. 2022. PMID: 34933568 Clinical Trial.
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.
Bettini E, Stahl SM, De Martin S, Mattarei A, Sgrignani J, Carignani C, Nola S, Locatelli P, Pappagallo M, Inturrisi CE, Bifari F, Cavalli A, Alimonti A, Pani L, Fava M, Traversa S, Folli F, Manfredi PL. Bettini E, et al. Pharmaceuticals (Basel). 2022 Aug 13;15(8):997. doi: 10.3390/ph15080997. Pharmaceuticals (Basel). 2022. PMID: 36015145 Free PMC article.
Discovery of Pyrazolo[1,5-a]pyrazin-4-ones as Potent and Brain Penetrant GluN2A-Selective Positive Allosteric Modulators Reducing AMPA Receptor Binding Activity.
Sakurai F, Yukawa T, Kina A, Murakami M, Takami K, Morimoto S, Seto M, Kamata M, Yamashita T, Nakashima K, Narita N, Bettini E, Ugolini A, Corsi M, Hasui T. Sakurai F, et al. Among authors: bettini e. Bioorg Med Chem. 2022 Feb 15;56:116576. doi: 10.1016/j.bmc.2021.116576. Epub 2021 Dec 16. Bioorg Med Chem. 2022. PMID: 35051811 Free article.
A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.
Davies DJ, Crowe M, Lucas N, Quinn J, Miller DD, Pritchard S, Grose D, Bettini E, Calcinaghi N, Virginio C, Abberley L, Goldsmith P, Michel AD, Chessell IP, Kew JN, Miller ND, Gunthorpe MJ. Davies DJ, et al. Among authors: bettini e. Bioorg Med Chem Lett. 2012 Apr 1;22(7):2620-3. doi: 10.1016/j.bmcl.2012.01.108. Epub 2012 Feb 6. Bioorg Med Chem Lett. 2012. PMID: 22366657
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.
Stahl SM, De Martin S, Mattarei A, Bettini E, Pani L, Guidetti C, Folli F, de Somer M, Traversa S, Inturrisi CE, Pappagallo M, Gentilucci M, Alimonti A, Fava M, Manfredi PL. Stahl SM, et al. Among authors: bettini e. Int J Mol Sci. 2022 Oct 13;23(20):12196. doi: 10.3390/ijms232012196. Int J Mol Sci. 2022. PMID: 36293063 Free PMC article.
Design and synthesis of 6-methylpyridin-2-one derivatives as novel and potent GluN2A positive allosteric modulators for the treatment of cognitive impairment.
Yukawa T, Yamashita T, Imaeda T, Kakei H, Hashizume S, Nakamura M, Daini M, Okabe A, Nakashima K, Harada A, Narita N, Bettini E, Ugolini A, Corsi M, Hasui T. Yukawa T, et al. Among authors: bettini e. Bioorg Med Chem. 2023 Feb 1;79:117150. doi: 10.1016/j.bmc.2022.117150. Epub 2022 Dec 24. Bioorg Med Chem. 2023. PMID: 36640594 Free article.
16 results